Globenewswireยท2025-03-10 10:03Core Insights - Fennec Pharmaceuticals reported a significant increase in net product sales for PEDMARK, achieving $29.6 million for the full fiscal year 2024, which is a 40% increase year-over-year, and $7.9 million in Q4 2024, reflecting a 13% increase from the previous quarter [1][11][32] - The company has strengthened its leadership team and is focused on expanding the adoption of PEDMARK in academic institutions and new patient segments, particularly in the adolescent and young adult (AYA) market [3][32] - Fennec has successfully launched PEDMARQSI in the UK and Germany, enhancing global access to its product aimed at preventing cisplatin-induced hearing loss in pediatric patients [1][6][32] Financial Performance - For the fiscal year 2024, total revenue reached $47.5 million, with net product sales contributing $29.6 million, compared to $21.3 million in 2023 [11][12] - The company reported a cash position of $26.6 million as of December 31, 2024, with a notable increase in cash and cash equivalents of $13.4 million from the previous year [11][14] - Selling and marketing expenses increased to $18.4 million for FY 2024, up from $12.1 million in FY 2023, reflecting the company's efforts to expand outreach [11][12] Strategic Developments - Fennec completed an early repayment of $13 million of its convertible debt facility, optimizing its balance sheet and saving approximately $1.5 million in future interest payments [1][6] - The company is advancing its efforts to include PEDMARK in the NCCN Drug and Biologics Compendium, which is crucial for expanding access and reimbursement pathways [6][32] - A clinical trial in Japan (STS-J01) is fully enrolled, with results expected in the second half of 2025, potentially leading to registration of PEDMARK in Japan [1][6]